Filing Flows › Health Care › Voyager Therapeutics (VYGR)
Voyager Therapeutics (VYGR) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Voyager Therapeutics (VYGR) Q3 2026 earnings results →
Q3 2026 Revenue down 70% year over year to $4.0M · 615¢ of every $1 of revenue lost · operating margin -658.2%
Voyager Therapeutics made $4.0M in Q3 2026 (-70% Y/Y). Operating margin -658.2%, net loss $24.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $4.0M in Q3 2026, down 70% year over year and up 27% from the previous quarter.
Operating costs exceeded revenue by $26.4M, an operating margin of -658.2%. Total costs fell 31% while revenue fell 70%. The quarter ended with a net loss of $24.7M, wider than the previous quarter's $24.5M loss.
Operating cash flow was −$19.7M. Non-cash charges added back $836K of depreciation and $2.6M of share-based compensation. Working capital and other items added $1.6M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $4.0M | -70% | -658.2% | −$24.7M | −$19.7M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $3.2M | -39% | -833.9% | −$24.5M | −$25.8M |
| Q1 2026 | 10-Q | May 7, 2026 | $2.6M | -60% | n/m | −$27.9M | −$33.4M |
| Q4 2025 | 10-K | Mar 9, 2026 | $15.3M | +144% | -195.2% | −$27.4M | −$30.3M |
| Q3 2025 | 10-Q | Nov 10, 2025 | $13.4M | -46% | -228.9% | −$27.9M | −$31.0M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $5.2M | -82% | -704.3% | −$33.4M | −$33.3M |
| Q1 2025 | 10-Q | May 6, 2025 | $6.5M | -67% | -536.0% | −$31.0M | −$37.9M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
About Voyager Therapeutics
We are a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Our pipeline includes programs for Alzheimer’s disease, or AD; Friedreich’s ataxia, or FA; Parkinson’s disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of our programs are derived from our TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which we have used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing.
In its own words, from its 10-K, filed Mar 9, 2026.
Voyager Therapeutics against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -70% against the peers' median +11%. Operating margin: -658.2% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| VYGR Voyager Therapeutics | Q3 2026 | $4.0M | -70% | -658.2% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Voyager Therapeutics 10-Q on SEC EDGAR · CIK 1640266 · Biological Products, (No Diagnostic Substances)
13F: who owns VYGR and who is buying
More on VYGR
- How Voyager Therapeutics makes money: revenue by segment
- Voyager Therapeutics next earnings date and what analysts expect
- Voyager Therapeutics stock forecast, price target and fair value
- Who owns Voyager Therapeutics stock: holders, funds and Congress trades
- Voyager Therapeutics recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results